Phase 3 Readout

SGP: Phase 3 Topline: A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy

Name: Phase 3 Topline: A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy
Start: 2031-03-31
End: 2031-03-31

March 31, 2031. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: March 31, 2031
Company: SpyGlass Pharma Inc. (SGP)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy

March 31, 2031

SGP overview →

Company: SpyGlass Pharma Inc. (SGP)
Indication: Ocular Hypertension; Cataract; Glaucoma